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National and international drug monitoring surveys (1-3 ) document a high prevalence of cannabis intake. Cannabis was the most common illicit drug identified among drivers positive for potentially impairing drugs in a 2007 survey (4 ) . Oral fluid (OF) 2 drug testing in workplace, pain management, drug treatment, and driving under the influence of drugs (DUID) programs is increasing. Elucidating cannabinoid OF pharmacokinetics after controlled smoked cannabis is essential for determining drug detection windows, finding markers of recent smoking, and minimizing potential for passive environmental smoke contamination. The ideal drug detection window varies depending on the goals and design of drug-testing programs. For workplace, pain management, and drug treatment research follow-up visits, a long drug detection window is ideal because testing opportunities are widely separated. Drug testing during accident investigations or "for cause" testing, however, is focused on recent use and potential impairment. Additionally, drug treatment programs may test once, twice, or 3 times a week to evaluate abstinence and relapse, making an intermediate detection window ideal. A key characteristic would be the ability to differentiate new drug intake from residual drug excretion. A short detection window comparable to the period of cannabis intoxication and impairment is preferred for human performance testing. Controlled cannabis administration and sequestration of participants on closed research units to eliminate self-administered drugs provide data for rigorously determining windows of drug detection in OF and improving result interpretation. ⌬
9
-Tetrahydrocannabinolic acid in cannabis undergoes decarboxylation at high temperatures to produce ⌬ 9 -tetrahydrocannabinol (THC), the primary psychoactive constituent (5 ) . THC is metabolized to multiple phase 1 metabolites, predominantly 11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-THC (THCCOOH), with further phase 2 conjugation with glucuronic acid and sulfate, facilitating elimination (6 ) . Another cannabinoid, cannabidiol (CBD) is not psychoactive but has potential therapeutic applications (7, 8 ) ; some investigators suggest that CBD may attenuate THC-induced tachycardia, euphoria, and anxiety (9, 10 ) . Cannabinol (CBN), a degradation product of THC oxidation, is approximately 10% as potent as THC and increases as cannabis ages (11, 12 ) .
Defining the appearance, relative concentrations, and duration of multiple cannabinoids in OF will improve OF test interpretation. OF contamination was recently documented in nonsmoking controls sitting in close proximity to cannabis smokers for 3 h (13 ). THC and CBN were present, but THCCOOH and CBD were not. THCCOOH was identified in OF samples in ng/L concentrations (14 -16 ) . Milman et al. (17 ) later characterized the time course of THCCOOH OF concentrations after self-administered smoked cannabis, multiple 20-mg oral THC doses, and 22-h monitored abstinence in chronic daily cannabis smokers. Monitoring THCCOOH that is not present in cannabis smoke (18 ) may document intentional cannabis intake and minimize the potential for passive cannabis contamination.
We quantified THC, CBD, CBN, and THCCOOH OF concentrations before and after ad libitum smoking of a single cannabis cigarette to (a) determine OF cannabinoid disposition, (b) evaluate appropriate markers and cutoff concentrations for different drug testing programs, and (c) assess cannabinoid OF collection with the Immunalysis Quantisal™ device.
Materials and Methods

PARTICIPANTS
We recruited cannabis smokers (age 18 -45 years) with a mean minimum cannabis intake of at least twice per month during the 3 months before study entry and a positive urine cannabinoid test. Additional inclusion criteria were peripheral veins suitable for venipuncture, blood pressure Յ140 mmHg systolic and 90 mmHg diastolic, heart rate Յ100 beats per minute, and electrocardiogram and 3-min rhythm strip without clinically relevant abnormalities. Exclusion criteria were history or presence of any clinically significant illness or adverse event associated with cannabis intoxication, donation of more than 450 mL blood within prior 30 days, interest or participation in drug abuse treatment within prior 60 days, and pregnancy or nursing.
SMOKED CANNABIS ADMINISTRATION
Participants resided on a closed clinical unit the night before (required) and after (optional) drug administration. Baseline measures for test parameters and biological samples were collected before drug administration. Mean (SD) cannabis cigarette weight was 0.79 (0.16) g and contained 6.8% (0.2%) THC, 0.25% (0.08%) CBD, and 0.21% (0.02%) CBN, yielding 54, 2.0, and 1.7 mg per cigarette, respectively. After ad libitum smoking (maximum 10 min), participants provided OF samples up to 22 h after smoking initiation. Participants were given breakfast 2 h before and lunch 2.5 h after dosing. Drinking water was prohibited 15 min before each OF collection. The study was approved by the National Institute on Drug Abuse Institutional Review Board, and participants gave voluntary written informed consent.
OF SAMPLE COLLECTION AND ANALYSIS
OF was collected with the Quantisal device (Immunalysis) at 0.5 h before and 0.25, 0.5, 1, 2, 3, 4, 6, and 22 h after the start of cannabis smoking. The device consists of an absorptive cellulose pad, a volume adequacy indicator that turns blue upon collection of 1.0 (0.1) mL OF, and a plastic tube containing 3 mL elution/ stabilizing buffer, yielding a 1:4 OF dilution. Samples collected at all time points except 22 h were analyzed within 24 h after refrigeration at 4°C; 22 h samples were stored at Ϫ20°C until analysis 7 days later.
We quantified THC, CBD, CBN, 11-OH-THC, and THCCOOH in OF by use of a published method (15 ) . Participants' OF samples were diluted with drugfree OF-Quantisal buffer mixture if analyte concentrations exceeded the upper limit of linearity. Limits of quantification (LOQs) were 0.5 g/L for THC, CBD, and 11-OH-THC; 1 g/L for CBN; and 7.5 ng/L for THCCOOH. Intraassay imprecision was 2.2%-6.6%, and interassay imprecision was Ͻ5.2%. Analytical recovery was within 13.8% of target.
DATA ANALYSIS
We used IBM SPSS Statistics version 18.0 for Windows and Microsoft Excel for statistical evaluation. Cannabinoid concentrations were log-transformed due to outliers and consequent nonnormal distributions. We analyzed correlations by nonparametric Spearman correlation test; group medians and distributions were compared with nonparametric Fisher exact test and Mann-Whitney U-test. Values below LOQ were considered as one-tenth the LOQ. Results with P Ͻ 0.05 were considered significant.
Results
Ten cannabis smokers (9 men, 1 women; ages 18 -45 years) spent the night before controlled administration at the secure research unit ensuring 15-to 20-h monitored abstinence. On completion of cannabis smoking the next day, participants provided 80 OF samples 0.5 h before and 0.25, 0.5, 1, 2, 3, 4, and 6 h after the start of smoking; 6 stayed for an additional night, providing 22 h samples. Participants reported median (range) cannabis smoking for 11.0 (8.5-14) of the last 14 days before screening. Median (range) age of first cannabis use was 15.5 (12-22) years old; lifetime duration of cannabis smoking was 9.0 (2-25) years. Participants' body mass indices ranged from 18.1 to 32.0. Additional demographic data are presented in Table 1 .
At 0.5 h before smoking, 4 participants were positive for THC (range 2.0 -13.6 g/L) and 9 for THC-COOH (11.8 -359 ng/L) owing to previously selfadministered smoked cannabis. CBD and CBN were not detected. The Quantisal collection device indicator showed low-volume collections for all 0.25-h, 6 0.5-h, 5 1-h, and 1 2-h sample, owing to dry mouth after smoking. In the participant negative for THC and THC-COOH at baseline, positive results for both analytes were observed 0.25 h after the start of smoking despite a low-volume collection.
Maximum OF THC concentrations occurred at or before the first sample (0.25 h) after the start of smoking for all participants, except for 1 participant who had a 0. CBD and CBN had time courses similar to that of THC, with concentrations generally an order of magnitude lower. Maximum CBD and CBN concentrations occurred at or before the first sample (0.25 h) after the start of smoking for all participants except for the same participant with peak THC concentration at 0.5 h. At 0.25 h postdose, CBD and CBN concentrations were 30.4 (2.6 -588) and 49.0 (4.8 -1558) g/L, respectively, decreasing by Ն95% 3 h after smoking to 0.9 (ϽLOQ-7.6) and 1.2 (ϽLOQ-17.3) g/L, respectively. Three participants were positive for CBD and CBN at 6 h, with concentrations Ͻ5 g/L; none were positive at 22 h.
Maximum THCCOOH concentrations generally occurred 1-2 h after the start of smoking, except in 2 participants with the highest concentrations at 0. Fig. 1 , with individual data summarized in Table 2 . THC concentrations were strongly correlated with CBD ( ϭ 0.976; n ϭ 86; P Ͻ 0.001) and CBN ( ϭ 0.971; n ϭ 86, P Ͻ 0.001) concentrations, with moderate correlation to THCCOOH ( ϭ 0.405; n ϭ 86; P Ͻ 0.001) concentrations. At each time point from 0.25 to 6 h (n ϭ 10), correlation coefficients for THC to CBD or CBN were significant (P Ͻ 0.005) and Ͼ 0.8, whereas correlation coefficients for THC and THC-COOH were Յ0.63 and nonsignificant (P Ն 0.05) from 0.25 to 6 h. THC concentrations 0.25 h after smoking were significantly correlated with lifetime years of cannabis smoking ( ϭ 0.948; P Ͻ 0.001) but not with body mass index, typical number of joints smoked per day, days since last smoked, or time taken to complete smoking (P Ͼ 0.05); THCCOOH concentrations were not significantly correlated with any of the above variables (all P Ͼ 0.05). Baseline THC concentrations were Ͻ1% (median 0.0%) of 0.25 h concentrations, whereas baseline THCCOOH concentrations ranged from 8% to 79% (49%) of 0.25 THCCOOH concentrations.
Participants with durations of lifetime cannabis smoking Ͻ10 years had significantly lower maximum concentrations (C max ) (P ϭ 0.008) for THC than participants with smoking durations Ͼ10 years (Fig. 2, A Error bars indicate interquartile ranges. Inset provides additional details for median THCCOOH concentrations over time. 
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Clinical Chemistry 58:4 (2012) 751 and C). The corresponding THCCOOH concentrations are shown in Fig. 2 , B and D; there were no significant differences in THCCOOH concentrations between groups. Median (range) THC C max for the 5 participants smoking Ͻ10 years was 373 (68.0 -588) g/L; THCCOOH was 52.2 (20.6 -320) ng/L. For the 5 participants who smoked Ն10 years, median THC and THCCOOH C max were 1524 (700 -10 284) and 212 (73.5-763) ng/L, respectively. Large intersubject variability was also observed in other cannabinoid concentrations. At 6 h postsmoking, all 10 participants' OF THC concentrations were greater than at baseline. By 22 h, however, 4 of 6 participants had THC ϽLOQ or lower than baseline concentrations. THCCOOH concentrations were more variable. Seven of 10 participants' THCCOOH OF concentrations were higher at 6 h than at baseline. By 22 h, 4 of 6 THCCOOH concentrations were lower than those before smoking. THC and THC-COOH concentration differences from baseline at 6 and 22 h are shown in Fig. 3 . At the Substance Abuse and Mental Health Services Administration (SAM-HSA) proposed 2-g/L THC cutoff, all participants were positive at 6 h and 2 of 6 at 22 h. At the 1-g/L driving under the influence of drugs, alcohol, and medicines (DRUID) European Union program THC cutoff, all participants were positive at 6 h and 3 of 6 at 22 h. We explored other possible cutoffs (
and THC Ն1-2 g/L ϩ THCCOOH Ն20, 30, 40, and 50 ng/L) and related detection windows to meet different drugtesting program goals (Fig. 4) . Last detection times were dependent on CBD, CBN, or THCCOOH, not THC concentrations, within the narrow 1-to 2-g/L cutoff range. Thus, when 2 cannabinoids were included in the combined analyte cutoffs, last detection times did not change whether THC Ն1, 1.5, or 2 g/L was used.
Discussion
The present study comprehensively characterized THC, CBD, CBN, and THCCOOH OF disposition after smoking of a single cannabis cigarette. Pharmacokinetic properties of cannabinoids in OF other than THC have not been adequately described. Also, for the first time, samples (all but 22-h samples) were refrigerated and analyzed within 24 h of collection to minimize concentration changes due to analyte instability. THC was stable under refrigerated conditions for 14 days in fortified OF samples (19 ) , but long-term stability of other cannabinoid analytes and THC stability in authentic OF samples have not been evaluated. Initial high OF THC, CBD, and CBN concentrations primarily reflected contamination of the oral mucosa directly with cannabinoids present in cannabis smoke. OF concentrations were influenced by cannabinoid concentrations in the cannabis plant, smoking topography (20 ) , THC pyrolysis (21 ), and sidestream smoke losses. Participants can titrate the delivered drug dose, leading to high intra-and intersubject variability in blood THC concentrations even in studies where smoking topography was tightly controlled (22 ) . Ad libitum smoking in this study introduced additional variability, but also provided more realistic concentrations by reflecting authentic smoking behavior while minimizing adverse events.
Our observed THC concentrations of 68 -10 284 g/L agree with those reported in other cannabinoid smoking studies. Niedbala et al. (26 ) observed OF THC as high as 5800 g/L 0.2 h after a cannabis cigarette containing 3.55% THC. In the present study, the high initial THC concentrations decreased to medians of 94.1 and 9.4 g/L at 2 and 6 h, respectively. Other studies reported 4 -54 and ϽLOQ to 17 g/L at 2 and 6 h postdose, respectively (23, 25, 26 ) . At 22 h, 4 of 6 participants were positive in our study, similar to reported THC detection at or beyond 24 h (25-28 ) . Median CBN concentrations 0.25-6 h postsmoking were 1%-50% higher than median CBD concentrations. Moore et al. (29 ) reported OF CBN, but not CBD, after cannabis smoking. The relatively high THC, CBD, and CBN concentrations detected in the present study could be due to higher cannabinoid content in the cigarette, analysis within 24 h (minimizing degradation), and/or participation by experienced chronic cannabis smokers whose smoking topography may have resulted in inhalation of higher cannabinoid amounts. Participant K, who had the lowest THC, CBD, and CBN concentrations throughout, selfreported smoking only 2 joints per day for 2 years. In contrast, participant I, who had the highest THC, CBD, and CBN concentrations, reported smoking 6 joints per day for 22 years. Toennes et al. (30 ) observed significantly higher maximum OF THC concentrations in chronic vs occasional smokers 5 min after 1 cannabis cigarette containing 500 g THC/kg body weight. OF cannabinoid concentrations also can be affected by recovery of analytes from the collection device and extraction efficiency of the sample preparation assay.
THCCOOH is not present in cannabis smoke (18 ) , and consequently OF THCCOOH concentrations likely reflect hepatic or oral mucosal metabolism following systemic THC ingestion. CYP2C expression was documented in human buccal (31 ) and tongue (32 ) cells; this enzyme is important to 11-OH-THC and THCCOOH formation from THC (33 ) . In the present study, THCCOOH peak concentrations occurred 1-2 h after smoking, although maximum concentrations occurred at 0.25 h for participants D and K. Multiple factors may have contributed to these findings, including residual THCCOOH concentrations and low-volume collection at these time points. Clinical research on THCCOOH pharmacokinetic properties in OF is limited. One study reported OF THC-COOH concentrations of Ͻ134 ng/L 0.25-8 h after smoking in 1 participant (14 ) . Even after 37 oral THC doses, no Ͼ1118 ng/L THCCOOH was observed (17 ) . Likewise, even at its peak, OF THCCOOH was Ͻ764 ng/L in all participants. For participant L, THCCOOH concentrations did not fall below 230 ng/L, but clearly observable blood in the OF samples most likely contributed to these high concentrations. Whole blood THCCOOH concentrations in participant L were 38 400 ng/L at baseline and 79 900 ng/L at peak (34 ) . His whole blood CBD and CBN were ϽLOQ within 0.5 h, with maximum concentrations Յ2.1 g/L, much less than those detected in OF. Whole blood THC could have contributed; as the peak occurred at 0.25 h in OF and whole blood, OF THC concentration was 1524 g/L whereas whole blood THC was 62.7 g/L. OF samples collected with noticeable blood should be recollected to prevent inaccurate interpretation.
Sample volume is another important issue to be considered in OF collection. Twenty-two of 86 samples collected within 2 h after smoking cannabis had volumes Ͻ1 mL based on collection device indicator failures, but still had a high prevalence of positive tests (all positive for THC, CBD and CBN; 2 negative for THC-COOH). These data and the findings of others (35 ) suggest that low-volume samples should not be discarded, as many may be positive for stimulant or cannabinoid drugs. Current proposed SAMHSA guidelines suggest discarding low-volume samples and initiating a new collection. We suggest that lowvolume OF collections should be analyzed, with a subsequent full 1-mL OF collection also tested to avoid false-negative results that could occur owing to greater dilution with elution buffer in low-volume samples.
We previously evaluated potential cannabinoid OF cutoffs in a population of chronic daily cannabis smokers during 4 -33 days of abstinence (28 ) . Including CBD, CBN, or THCCOOH with a THC cutoff could document recent cannabis exposure and rule out residual THC excretion. The present study evaluated multiple cutoffs following acute cannabis smoking. Cutoffs with THC and CBD or CBN limited the detection window to Յ6 h, equivalent to a cognitive and motor performance impairment window suggested by Ramaekers et al. (36 ) . Others also reported impairment in psychomotor tasks from 15 min to 4 h after cannabis ingestion (37, 38 ) . In DUID cases, it is important to identify recent cannabis exposure of Ͻ8 -12 h, especially as cannabis was often the most prevalent drug identified in injured drivers (39 ) . However, CBD and CBN content in the cigarette can vary due to selective breeding procedures, composition of plant material, and storage conditions (6 ) , and tests for CBD and CBN do not protect against passive contamination from environmental cannabis smoke.
The current proposed THC confirmation cutoffs of Ն1 g/L (DRUID) and Ն2 g/L (SAMHSA) offer longer detection times but do not adequately protect against the possibility of passive cannabis smoke contamination. Cutoffs including THCCOOH with or without THC minimize the issue of passive exposure, although large intersubject variability in THCCOOH detection windows was observed. We noted in this study and in our previous work (28 ) that THCCOOH generally provides a longer detection time than THC. This longer detection time is a deterrent to drug intake. Incorporating additional cannabinoids or higher cutoff concentrations can shorten detection times for other testing programs, including DUID. Further research is needed to fully define OF cannabinoid detection windows, especially with the inclusion of additional occasional smokers.
These controlled smoked cannabis administration data provide valuable information for interpretation of OF cannabinoid concentrations, and suggest preliminary cutoffs and collection procedures for OF drug testing programs.
